Create a free research account to view current pricing and place an order.
Mechanism of action
AOD-9604 is a modified fragment of the hGH 176-191 region. It is researched for lipolysis-oriented and adipocyte metabolic signaling without the broader anabolic receptor profile associated with full-length human growth hormone.
Half-life & pharmacokinetics
Half-life: Short acting; human PK limited.
Human PK standardization is limited. Operationally treated as short acting; many research protocols use daily timing to preserve interpretation of metabolic response.
Research dosing reference
250-500 mcg daily; commonly interpreted as a metabolic/lipolysis adjunct.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 250 mcg | 10 units |
| 500 mcg | 20 units |
| 750 mcg | 30 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
Reconstitution & concentration
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 5 mg | 2 mL BAC Water | 0.025 mg/unit |
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
Injection timing
Daily administration; morning or pre-activity timing is often preferred for metabolic interpretation.
Beginner escalation
Begin at the low end to evaluate energy, appetite, and GI response before increasing.
Side-effect mitigation
Monitor GI upset, appetite changes, fatigue, injection-site tolerance, and hydration status.
Stack compatibility
Often paired conceptually with GLP/metabolic protocols or mitochondrial agents; avoid adding too many appetite-modulating agents simultaneously.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Commonly structured as 4-12 week metabolic blocks followed by reassessment of energy, appetite, body-composition trend, GI tolerance, and objective need before extension or repeat course.
Frequently asked questions
What is AOD-9604 and how does it work?
AOD-9604 is a modified fragment of the hGH 176-191 region. It is researched for lipolysis-oriented and adipocyte metabolic signaling without the broader anabolic receptor profile associated with full-length human growth hormone.
What is the half-life of AOD-9604?
AOD-9604: Short acting; human PK limited. Human PK standardization is limited. Operationally treated as short acting; many research protocols use daily timing to preserve interpretation of metabolic response.
How is AOD-9604 reconstituted for research?
Preferred reconstitution for the 5 mg vial is 2 mL BAC Water, giving 0.025 mg/unit. Always confirm concentration math before any use. Research use only.
Is AOD-9604 FDA approved?
No. AOD-9604 is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.
AOD-9604 product overview · AOD-9604 cost · All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration